Skip to main content

Cencora Inc. Value Stock - Dividend - Research Selection

Amerisourcebergen

ISIN: US03073E1055 , WKN: 766149

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, outsourced compounded sterile preparations, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and other alternate site pharmacies, and other customers. It also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; and packaging solutions to various institutional and retail healthcare providers. In addition, this segment provides pharmaceutical distribution and other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics; distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and offers third party logistics and outcomes research, and other services for biotechnology and other pharmaceutical manufacturers. The company\'s Other segment provides commercialization support services, including reimbursement support programs, outcomes research, contract field staffing, patient assistance and co-pay assistance programs, adherence programs, risk mitigation services, and other market access programs to pharmaceutical and biotechnology manufacturers; specialty transportation and logistics services for the biopharmaceutical industry; and animal health care products. It markets its products and services through independent sales forces and marketing organizations. AmerisourceBergen Corporation was founded in 1985 and is headquartered in Chesterbrook, Pennsylvania.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


COR Stock Down Nearly 18% YTD: Should You Buy, Hold or Sell?

2026-06-18
COR shares are down 18% YTD, but rising EPS guidance, specialty pharma growth and strategic expansion could make this pullback worth watching.

Cencora Launches Enhanced Nucleus Solution for Specialty Practices

2026-06-18
COR's enhanced Nucleus platform targets complex specialty medication workflows, with a pilot underway across more than 20 physician practice sites.

Bet on 5 Top-Ranked Stocks With Rising P/E for Solid Returns

2026-06-18
Rising P/E ratios can signal confidence and momentum. Discover 5 stocks backed by strong earnings growth and upside potential.

Add These 4 GARP Stocks to Your Portfolio to Receive Handsome Returns

2026-06-17
The GARP strategy helps investors gain exposure to stocks that have solid prospects and are trading at a discount. TPR, VRT, CLS and COR are some such stocks.

Cencora Launches Next-Generation Nucleus® Solution with Multi-Site Pilot Across Specialty Physician Practices

2026-06-17
CONSHOHOCKEN, Pa., June 17, 2026--Cencora, a global pharmaceutical solutions company, today announced a multi-site pilot of its enhanced Nucleus® inventory management solution, designed to help specialty physician practices manage increasingly complex medication workflows with greater efficiency, visibility and control.

Cencora Announces Samantha Hammock as Chief Human Resources Officer

2026-06-15
CONSHOHOCKEN, Pa., June 15, 2026--Cencora, Inc. (NYSE: COR) today announced that Silvana Battaglia, Executive Vice President and Chief Human Resources Officer (CHRO), has announced she will retire from the company following a distinguished seven-year tenure. She will be succeeded by Samantha (Sam) Hammock, who will join Cencora as Executive Vice President and CHRO, effective July 13, 2026.

Cardinal Health Stock: Is CAH Outperforming the Healthcare Sector?

2026-06-15
Cardinal Health has outperformed the healthcare sector over the past year. Moreover, Wall Street analysts are strongly bullish on the stock.

Assessing Cencora (COR) Valuation After Kite CAR T Distribution Deal And Upcoming CFO Transition

2026-06-10
Cencora (COR) has attracted fresh attention after agreeing to support distribution of Kite’s FDA approved CAR T cell therapies, while also planning a CFO transition to Eva C. Boratto in June 2026. See our latest analysis for Cencora. Recent news around the Kite collaboration and upcoming CFO change comes as the stock price has risen 2.00% over 1 day and 7.08% over 30 days, but is still down 20.19% over 90 days. The 5 year total shareholder return of 147.29% points to a much stronger longer...

Cencora Kite Deal Highlights CAR T Growth And Undervalued Share Price Potential

2026-06-10
Cencora (NYSE:COR) has entered a major U.S. distribution partnership with Kite Pharma, a Gilead company. The agreement focuses on market access and distribution support for FDA approved CAR T cell therapies across U.S. treatment centers. The collaboration is aimed at easing logistical and administrative hurdles for healthcare providers using these personalized cancer treatments. Cencora comes into this Kite agreement with a mixed share price record. The stock is trading at $279.57, with...

Barclays Maintains Overweight on Cencora, Lowers Price Target to $350

2026-06-10
Barclays analyst Glen Santangelo maintains Cencora (NYSE:COR) with a Overweight and lowers the price target from $425 to $350.